NEW YORK (GenomeWeb News) – CML HealthCare today said that it has licensed exclusive rights to offer Mitomics' prostate cancer test in Canada.

The Prostate Core Mitomic Test is a mitochondrial DNA-based test that detects malignant cells in biopsy tissue. The firms said it can detect mitochondrial DNA alterations in benign tissue when a tumor is present in adjacent tissue, and they noted that the test offers 85 percent sensitivity with a negative predictive value of 92 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.